Clinical trial NCT05190432: Taxifolin/ergothioneine and Immune Biomarkers in Healthy Volunteers (TaxEr)
Official title: A Pilot Study of Dietary Taxifolin/Dihydroquercetin and Ergothioneine and Immune Biomarkers in Healthy Volunteers
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Antioxidative Stress
Cold
Influenza
Aging
Inflammation
Keywords: Phagocytosis
Immunosenecence
Cytokine
Antioxidant
Metabolome
Microbiome
Lead sponsor: University of Southampton
Sponsor class: OTHER
Collaborators: name: Blue California
First posted: 2022-01-13
Enrollment: 90
Sex: ALL
Minimum age (years): 50
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: A n=90 study (3 treatment arms, each n=30) providing participants with either 250mg/day Taxifolin/DHQ, 80mg/day Ergothioneine, or control.
Primary purpose: BASIC_SCIENCE

Brief summary: The complexities of the immune system make measuring the impact of dietary interventions upon its function challenging. The immune system is highly responsive to environmental influences, including the diet. An individual's diet provides the energy required to mount a strong and protective immune response, the building blocks required for synthesis of immune mediators such as antibodies and cytokines, and can also indirectly affect immune function via changes in the gut microbiome. Immune function varies across the lifecourse, with a well understood decline in immune function with age, resulting in impaired vaccination responses and an increased risk of infections and of severe complications and mortality arising from common communicable diseases such as influenza. This impaired immunity with ageing is known as immunosenescence and this affects both innate and acquired arms of the immune system.

Detailed description: Expert guidance is available to inform the design of human nutrition trials to ensure they include the most relevant immunological outcomes (Albers, 2013). In this study, ex vivo phagocytosis and oxidative burst of immune cells will be the primary outcome, supported by other ex vivo immune measures of high clinical relevance including functional assessment of cytokine production and expression of activation markers.

Human nutritional trials frequently omit to monitor the degree of immunosenescence in participants, even amongst studies conducted amongst older adults. For example, a recent review of pre- and probiotic trials which assessed immune responses in older adults identified that only two of thirty-six studies assessed any marker of immunosenescence (Childs \& Calder, 2017).

Taxifolin/DHQ is a naturally occurring polyphenol found in apples, onions and other fruits and bark extracts. Ergothioneine is an amino acid found in mushrooms, oats and some bean varieties. We hypothesise that Taxifolin/DHQ and/or Ergothioneine will alter immune function via their established antioxidant effects, and that the effects observed will vary between older adults relative to their degree of immunosenescence.

Though current dietary guidelines advise consumption of 5 portions of fruits and vegetables per day, recent surveys reveal that fewer than 30% of adults achieve this. Antioxidants found within fruits and vegetables are understood to be one of the important aspects by which our diet can influence health. It is important to investigate the effects of such antioxidants through well designed and conducted human trials.

Eligibility criteria: Inclusion Criteria:

* age 50-65yr
* BMI 18.5-30kg/m2
* Willing to avoid consumption of foods rich in Taxifolin/DHQ and Ergothioneine during the study period
* Willing to avoid taking any other food supplements or high doses of vitamins during the study period
* Able to provide written informed consent.

Exclusion Criteria:

* Use of prescription medication which may influence immune function, such as anti-inflammatory or immunosuppressant medication
* Diabetes requiring any medication
* Liver cirrhosis
* A history of drug or alcohol misuse
* Asplenia or other acquired or congenital immunodeficiencies
* Any autoimmune disease including connective tissue diseases
* Malignancy
* Laboratory confirmed SARS-CoV-2 infection within last 3 months
* self-reported symptoms of acute or recent infection (including use of antibiotics within the last 3 months)

Primary outcomes:
measure: Phagocytosis activity by granulocytes ex vivo
timeFrame: 8 weeks post intervention
Secondary outcomes:
measure: Percentage phagocytosis by monocytes ex vivo
timeFrame: 4 weeks, 8 weeks, 3 months post intervention
measure: Phagocytosis activity by monocytes ex vivo
timeFrame: 4 weeks, 8 weeks, 3 months post intervention
measure: Percentage phagocytosis by granulocytes ex vivo
timeFrame: 4 weeks, 8 weeks, 3 months post intervention
measure: Phagocytosis activity by granulocytes ex vivo
timeFrame: 4 weeks, 3 months post intervention
measure: Percentage oxidative burst by monocytes ex vivo
timeFrame: 4 weeks, 8 weeks, 3 months post intervention
measure: Oxidative burst activity by monocytes ex vivo
timeFrame: 4 weeks, 8 weeks, 3 months post intervention
measure: Percentage oxidative burst by granulocytes ex vivo
timeFrame: 4 weeks, 8 weeks, 3 months post intervention
measure: Oxidative burst activity by granulocytes ex vivo
timeFrame: 4 weeks, 8 weeks, 3 months post intervention
measure: Frequencies of naive T cells
timeFrame: 8 weeks
measure: Frequencies of memory T cells
timeFrame: 8 weeks
measure: CD57 expression upon T cells.
timeFrame: 8 weeks
measure: CD28 expression upon T cells.
timeFrame: 8 weeks
measure: Plasma lipid peroxides
timeFrame: 8 weeks
measure: Urinary isoprostanes
timeFrame: 4 weeks, 8 weeks, 3 months post intervention
measure: Plasma isoprostanes
timeFrame: 4 weeks, 8 weeks, 3 months post intervention
measure: Cytokine production by cryopreserved peripheral blood mononuclear cells in response to lipopolyssaccharide
timeFrame: 4 weeks, 8 weeks
measure: Cytokine production by cryopreserved peripheral blood mononuclear cells in response to influenza or coronavirus vaccine products
timeFrame: 4 weeks, 8 weeks
measure: Metabolomic analysis of urine samples
timeFrame: 4 weeks, 8 weeks, 3 months post intervention
measure: Metabolomic analysis of serum samples
timeFrame: 4 weeks, 8 weeks, 3 months post intervention
measure: Faecal microbiome analysis
timeFrame: 4 weeks, 8 weeks, 3 months post intervention
measure: Incidence of self-reported seasonal cold, coronavirus and influenza-like illness.
timeFrame: 4 weeks, 8 weeks, 3 months post intervention
measure: Duration of self-reported illness.
timeFrame: 4 weeks, 8 weeks, 3 months post intervention
measure: Severity of self-reported illness.
timeFrame: 4 weeks, 8 weeks, 3 months post intervention
measure: Self-reported medication use.
timeFrame: 4 weeks, 8 weeks, 3 months post intervention
Other outcomes:
Locations:
city: Southampton
country: United Kingdom
facility: NIHR Southampton Biomedical Research Centre
state: Hampshire
Study officials:
affiliation: University of Southampton
name: Caroline E Childs, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Albers R, Bourdet-Sicard R, Braun D, Calder PC, Herz U, Lambert C, Lenoir-Wijnkoop I, Meheust A, Ouwehand A, Phothirath P, Sako T, Salminen S, Siemensma A, van Loveren H, Sack U. Monitoring immune modulation by nutrition in the general population: identifying and substantiating effects on human health. Br J Nutr. 2013 Aug;110 Suppl 2:S1-30. doi: 10.1017/S0007114513001505.
citation: Childs, C. E., & Calder, P. C. (2017). Modifying the gut microbiome through diet: effects on the immune system of elderly subjects. In T. Fulop, C. Franceschi, K. Hirokawa, & G. Pawelec (Eds.), Handbook of Immunosenescence Cham: Springer International Publishing AG. DOI: 10.1007/978-3-319-64597-1_160-1
citation: EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA); Turck D, Bresson JL, Burlingame B, Dean T, Fairweather-Tait S, Heinonen M, Hirsch-Ernst KI, Mangelsdorf I, McArdle HJ, Naska A, Neuhauser-Berthold M, Nowicka G, Pentieva K, Sanz Y, Siani A, Sjodin A, Stern M, Tome D, Vinceti M, Willatts P, Engel KH, Marchelli R, Poting A, Poulsen M, Schlatter J, Gelbmann W, Van Loveren H. Scientific Opinion on taxifolin-rich extract from Dahurian Larch (Larix gmelinii). EFSA J. 2017 Feb 14;15(2):e04682. doi: 10.2903/j.efsa.2017.4682. eCollection 2017 Feb.
citation: EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA); Turck D, Bresson JL, Burlingame B, Dean T, Fairweather-Tait S, Heinonen M, Hirsch-Ernst KI, Mangelsdorf I, McArdle HJ, Naska A, Neuhauser-Berthold M, Nowicka G, Pentieva K, Sanz Y, Siani A, Sjodin A, Stern M, Tome D, Vinceti M, Willatts P, Engel KH, Marchelli R, Poting A, Poulsen M, Schlatter JR, Ackerl R, van Loveren H. Statement on the safety of synthetic l-ergothioneine as a novel food - supplementary dietary exposure and safety assessment for infants and young children, pregnant and breastfeeding women. EFSA J. 2017 Nov 13;15(11):e05060. doi: 10.2903/j.efsa.2017.5060. eCollection 2017 Nov.
citation: Vega-Villa KR, Remsberg CM, Ohgami Y, Yanez JA, Takemoto JK, Andrews PK, Davies NM. Stereospecific high-performance liquid chromatography of taxifolin, applications in pharmacokinetics, and determination in tu fu ling (Rhizoma smilacis glabrae) and apple (Malus x domestica). Biomed Chromatogr. 2009 Jun;23(6):638-46. doi: 10.1002/bmc.1165.
citation: Ey J, Schomig E, Taubert D. Dietary sources and antioxidant effects of ergothioneine. J Agric Food Chem. 2007 Aug 8;55(16):6466-74. doi: 10.1021/jf071328f. Epub 2007 Jul 6.
citation: Przemska-Kosicka A, Childs CE, Enani S, Maidens C, Dong H, Dayel IB, Tuohy K, Todd S, Gosney MA, Yaqoob P. Effect of a synbiotic on the response to seasonal influenza vaccination is strongly influenced by degree of immunosenescence. Immun Ageing. 2016 Mar 15;13:6. doi: 10.1186/s12979-016-0061-4. eCollection 2016.
citation: Ohara O. [Rapid cDNA sequencing method using the polymerase chain reaction]. Tanpakushitsu Kakusan Koso. 1990 Oct;35(14):2319-28. No abstract available. Japanese.
citation: Taves DR. Minimization: a new method of assigning patients to treatment and control groups. Clin Pharmacol Ther. 1974 May;15(5):443-53. doi: 10.1002/cpt1974155443. No abstract available.